YOKOHAMA, Japan--(BUSINESS WIRE)--ReproCELL (JASDAQ:4978) was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology.
Through the acquisitions of Reinnervate Limited (Reinnervate, located in Europe) and BioServe Biotechnologies, Ltd. (BioServe, located in the United States), ReproCELL Group will accelerate its iPS cell business through the following synergistic effects:
1. The Establishment of Global Distribution Network
ReproCELL,
Reinnervate and BioServe already serve the same types of customers
including large pharmaceutical companies, biotechnology companies, major
universities and medical institutions in Europe and the United States,
respectively. The local sales and distribution expertise provided by
Reinnervate and BioServe will help grow ReproCELL’s market share in
Europe and North America. ReproCELL’s local presence in Japan and
extensive distribution networks in Asia will help to accelerate sales of
Reinnervate and BioServe products in Asia.
2. Technology synergy and new product introductions
(1) Next
Generation iPS cell products
Through the combination of
Reinnervate’s innovative 3D cell culture technologies and ReproCELL’s
iPS cell technologies, the next generation of iPS cell products with
better functionality and usability for customers will be developed and
launched globally.
(2) Patients-derived iPS Cell Products
Through
the acquisition of BioServe, ReproCELL will now have access to large
variety of patient derived cells in disease areas such as Alzheimer's,
Parkinsons and Cardiovascular disorders. This will accelerate the
development and commercialization of diverse patient-derived iPS cell
products where there is a rapidly growing market need.
ReproCELL will now aggressively promote both existing and new products derived from these technology synergies and leverage best practices from all three businesses in all territories.
[Reference]
Reinnervate Company
Outline
Reinnervate is a 2002 spin-out company from
Durham University, a center of excellence in cell biology research
located in County Durham, UK. Reinnervate’s Alvetex platform is based on
the research performed by Prof. Stefan Przyborski. Professor Przyborski
is considered to be one of the world’s leading experts in the field of
3D cell culture and as is Reinnervate’s Chief Scientific Officer, in
addition to his role as Professor of Cell Technology in the School of
Biological and Biomedical Science at Durham University. Reinnervate is a
leader in the fast-growing market of 3D cell culture. Alvetex 3D cell
culture enables scientist to grow tissue-like structures that better
mimic in vivo biology than current 2D monolayer methods. The potential
to improve the predictive nature of cell based assays by combining 3D
culture and iPSC-derived cell products is attracting a lot of interest
in the drug development industry.
Reinnervate’s products have a
wide range of applications in drug discovery screening and academic
research and are currently used by researchers in over 300 universities
and companies globally.
URL: http://reinnervate.com/
BioServe Company Outline
BioServe
was established in 1989 by researchers including Dr. Rama Modali, who
worked for NIH (National Institute of Health) and National Cancer
Institute as a molecular biologist. Located in Beltsville MD, USA,
BioServe reposits human biomaterials more than 600,000 samples including
human DNA, organ and serum samples, providing researchers in
Universities and Pharmaceutical Companies. BioServe has over 500
customers including large pharmaceutical companies, biotechnology
companies, diagnostic service companies, major universities and medical
institutions.
URL: http://www.bioserve.com/
